Skip to main content
Premium Trial:

Request an Annual Quote

Strong Consumables Sales Help Qiagen Post 20-Percent Revenue Gain in Q3

This article has been updated from a previous version, which incorrectly stated that 7 percent of Qiagen's third-quarter revenue came from Genaco Biomedical, instead of from acquisitions.
 
NEW YORK (GenomeWeb News) — Qiagen today said third-quarter revenues increased 20 percent as R&D spending rose 29 percent and profit increased 10 percent.
 
Total receipts for the three months ended Sept. 30 increased to $117.9 million from $98.6 million year over year, beating its guidance of $116 million.
 
The largest gains came from consumables sales, which conributed 20 percent to the growth. Around 7 percent of the quarter’s revenue came from acquisitions.
 
Sales in Asia also contributed to the company’s expansion as Qiagen saw a 63-percent increase in revenue in Asian markets.
 
R&D spending increased to $10.1 million from $7.8 million year over year.
 
The company said profit increased to $19.4 million from $17.6 million in the year-ago period.
 
Qiagen said it had around $492 million in cash and equivalents as of Sept. 30. 

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.